118 related articles for article (PubMed ID: 38102902)
1. Prostate cancer invading rectal serosa and anal sphincter treated with definitive radiation therapy: Case report and review of the literature.
Lee MJ
J Cancer Res Ther; 2023 Dec; ():. PubMed ID: 38102902
[TBL] [Abstract][Full Text] [Related]
2. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
[TBL] [Abstract][Full Text] [Related]
4. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
Zapatero A; Roch M; Castro Tejero P; Büchser D; Martin de Vidales C; González S; Rodríguez P; San Jose LA; Celada G; Murillo MT
Br J Radiol; 2022 Mar; 95(1131):20210683. PubMed ID: 34538073
[TBL] [Abstract][Full Text] [Related]
5. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
[TBL] [Abstract][Full Text] [Related]
6. The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy.
Mazzola R; Fersino S; Fiorentino A; Ricchetti F; Giaj Levra N; Di Paola G; Sicignano G; Naccarato S; Ruggieri R; Alongi F
Clin Transl Oncol; 2016 Mar; 18(3):317-21. PubMed ID: 26250766
[TBL] [Abstract][Full Text] [Related]
7. Whole-pelvic volumetric-modulated arc therapy for high-risk prostate cancer: treatment planning and acute toxicity.
Ishii K; Ogino R; Hosokawa Y; Fujioka C; Okada W; Nakahara R; Kawamorita R; Tada T; Hayashi Y; Nakajima T
J Radiat Res; 2015 Jan; 56(1):141-50. PubMed ID: 25304328
[TBL] [Abstract][Full Text] [Related]
8. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
[TBL] [Abstract][Full Text] [Related]
9. [Short-term efficacy comparison between preoperative three dimensional conformal radiotherapy and volumetric modulated arc therapy concurrently combined with chemotherapy in the treatment of locally advanced rectal carcinoma].
Xiao L; Yu X; Zhu Y; Xiao W; Zeng Z; Liu M; Zhang R; Gao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jul; 19(7):769-75. PubMed ID: 27452754
[TBL] [Abstract][Full Text] [Related]
10. Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
Yang Y; Liu Q; Jia B; Du X; Dai G; Liu H; Chen J; Zeng M; Wen K; Zhu Y; Wang Y; Feng L
Technol Cancer Res Treat; 2019 Jan; 18():1533033818824367. PubMed ID: 30803368
[TBL] [Abstract][Full Text] [Related]
11. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
[TBL] [Abstract][Full Text] [Related]
12. Pelvic radiation therapy with volumetric modulated arc therapy and intensity-modulated radiotherapy after renal transplant: A report of 3 cases.
Ileana PÁS; Rubi RP; Javier LRF; Sagrario MGMD; Haydeé FBC
Rep Pract Oncol Radiother; 2020; 25(4):548-555. PubMed ID: 32494227
[TBL] [Abstract][Full Text] [Related]
13. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
14. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature.
Nguyen PL; Devlin PM; Beard CJ; Orio PF; O'Leary MP; Wolfsberger LD; O'Farrell DA; Sweeney CM; Hadaschik BA; Hohenfellner M; Hatiboglu G
Brachytherapy; 2013; 12(1):77-83. PubMed ID: 22543116
[TBL] [Abstract][Full Text] [Related]
16. Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer.
Franzese C; Fogliata A; D'Agostino GR; Di Brina L; Comito T; Navarria P; Cozzi L; Scorsetti M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1301-1309. PubMed ID: 28271215
[TBL] [Abstract][Full Text] [Related]
17. Intensity modulated proton and photon therapy for early prostate cancer with or without transperineal injection of a polyethylen glycol spacer: a treatment planning comparison study.
Weber DC; Zilli T; Vallee JP; Rouzaud M; Miralbell R; Cozzi L
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e311-8. PubMed ID: 22999271
[TBL] [Abstract][Full Text] [Related]
18. Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer.
Cuccia F; Nicosia L; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Vitale C; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Jul; 196(7):628-636. PubMed ID: 32399638
[TBL] [Abstract][Full Text] [Related]
19. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiation therapy for prostate cancer: a study comparing 3-year genitourinary toxicity between CyberKnife and volumetric-modulated arc therapy by propensity score analysis.
Ito M; Yoshioka Y; Takase Y; Suzuki J; Takahashi H; Minami Y; Sakuragi A; Oshima Y; Okuda T; Suzuki K
Radiat Oncol; 2023 Feb; 18(1):39. PubMed ID: 36823674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
